NA13425
DNA from Fibroblast
Description:
EHLERS-DANLOS SYNDROME, TYPE VI
PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE; PLOD1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases |
Class |
Disorders of Connective Tissue, Muscle, and Bone |
Quantity |
10 µg |
Quantitation Method |
Please see our FAQ |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Sample Source
|
DNA from Fibroblast
|
Race
|
White
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
19 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
procollagen-lysine 5-dioxygenase |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 1.14.11.4; 24% activity. |
|
Gene |
PLOD1 |
Chromosomal Location |
1p36.3-p36.2 |
Allelic Variant 1 |
153454.0004; EHLERS-DANOLS SYNDROME TYPE VIA |
Identified Mutation |
3-BP DEL, GLU532DEL; Ha et al (1994) found compound heterozygosity of mutations in the PLOD gene in a male of Mexican-American ancestry born full term without premature rupture of fetal membranes to a nonconsanguineous couple. He was noted at birth to exhibit hemifacial asymmetry and dislocation of the right wrist and hip. Other features characteristic of E-D VI (225400) included myopia, hyperextensible and velvety skin, and hypotrophic wound healing. Bilateral herniorrhaphy and orchidopexy were performed at the age of 6 months, and Harrington rod placement for kyphoscoliosis at the age of 3 years. He was demonstrated to be ascorbate-responsive and did well from the age of 6 to approximately 14 years when he stopped taking ascorbate. These features were reported by Dembure et al. (1984, 1987), Elsas et al. (1978), and Miller et al. (1979). At the age of 15 years, he had spontaneous arterial rupture in the upper thigh. Bilateral venous thrombosis resulted from compression stasis which required fasciotomies. Pharmacologic amounts of ascorbate (5.0 g/d) were reinstituted and wound healing progressed normally. Amino acid analysis of the skin showed zero hydroxylysine per 1,000 residues with normal values being 5 per 1,000. Assay of lysyl hydroxylase activity in cultured dermal fibroblasts showed that the patient had a ratio of lysyl hydroxylase to prolyl hydroxylase that was 24% of the control values. An autosomal recessive mode of inheritance was deduced from the same assay performed on his parents' dermal fibroblasts, which showed 52 and 86% lysyl hydroxylase activity relative to prolyl hydroxylase activity, in the father and mother, respectively. Neither parent had clinical evidence of E-D VI. Ha et al. (1994) detected a G-to-A change that produced a gly678-to-arg codon change in a highly conserved region of the enzyme in the paternal allele of the proband. The maternal allele showed a 3-bp deletion that resulted in loss of residue glu532 (153454.0003). |
|
Gene |
PLOD1 |
Chromosomal Location |
1p36.3-p36.2 |
Allelic Variant 2 |
153454.0003; EHLERS-DANOLS SYNDROME TYPE VIA |
Identified Mutation |
GLY678ARG; Ha et al (1994) found compound heterozygosity of mutations in the PLOD gene in a male of Mexican-American ancestry born full term without premature rupture of fetal membranes to a nonconsanguineous couple. He was noted at birth to exhibit hemifacial asymmetry and dislocation of the right wrist and hip. Other features characteristic of E-D VI (225400) included myopia, hyperextensible and velvety skin, and hypotrophic wound healing. Bilateral herniorrhaphy and orchidopexy were performed at the age of 6 months, and Harrington rod placement for kyphoscoliosis at the age of 3 years. He was demonstrated to be ascorbate-responsive and did well from the age of 6 to approximately 14 years when he stopped taking ascorbate. These features were reported by Dembure et al. (1984, 1987), Elsas et al. (1978), and Miller et al. (1979). At the age of 15 years, he had spontaneous arterial rupture in the upper thigh. Bilateral venous thrombosis resulted from compression stasis which required fasciotomies. Pharmacologic amounts of ascorbate (5.0 g/d) were reinstituted and wound healing progressed normally. Amino acid analysis of the skin showed zero hydroxylysine per 1,000 residues with normal values being 5 per 1,000. Assay of lysyl hydroxylase activity in cultured dermal fibroblasts showed that the patient had a ratio of lysyl hydroxylase to prolyl hydroxylase that was 24% of the control values. An autosomal recessive mode of inheritance was deduced from the same assay performed on his parents' dermal fibroblasts, which showed 52 and 86% lysyl hydroxylase activity relative to prolyl hydroxylase activity, in the father and mother, respectively. Neither parent had clinical evidence of E-D VI. Ha et al. (1994) detected a G-to-A change that produced a gly678-to-arg codon change in a highly conserved region of the enzyme in the paternal allele of the proband. The maternal allele showed a 3-bp deletion that resulted in loss of residue glu532 (153454.0003). |
Remarks |
Mexican-American; hemifacial asymmetry & disloc of wrist & hip at birth; myopia, hyperextensible, soft & velvety skin, & hypotrophic wound healing at age 6; lysyl hydroxylase/prolyl hydroxylase is 24% of norm; donor subject is a compound heterozygote: one allele has a 3 bp deletion of the lysyl hydroxylase (PLOD1) gene that resulted in loss of residue glu532 [Glu532Del] and the second allele has a G>A change that produced a gly678-to-arg codon change in a highly conserved region of the enzyme |
Kellogg G, Thorsson B, Cai Y, Wisotzkey R, Pollock A, Akana M, Fox R, Jansen M, Gudmundsson EF, Patel B, Chang C, Jaremko M, Puig O, Gudnason V, Emilsson V, Molecular screening of familial hypercholesterolemia in Icelanders Scandinavian journal of clinical and laboratory investigation:1-7 2020 |
PubMed ID: 32706999 |
|
Ha VT, Marshall MK, Elsas LJ, Pinnell SR, Yeowell HN, A patient with Ehlers-Danlos syndrome type VI is a compound heterozygote for mutations in the lysyl hydroxylase gene. J Clin Invest93:1716-21 1994 |
PubMed ID: 8163671 |
|
Dembure PP, Janko AR, Priest JH, Elsas LJ, Ascorbate regulation of collagen biosynthesis in Ehlers-Danlos syndrome, type VI. Metabolism36:687-91 1987 |
PubMed ID: 3110540 |
|
Dembure PP, Priest JH, Snoddy SC, Elsas LJ, Genotyping and prenatal assessment of collagen lysyl hydroxylase deficiency in a family with Ehlers-Danlos syndrome type VI. Am J Hum Genet36:783-90 1984 |
PubMed ID: 6089551 |
dbSNP |
dbSNP ID: 22616 |
Gene Cards |
PLOD1 |
Gene Ontology |
GO:0005489 electron transporter activity |
|
GO:0005783 endoplasmic reticulum |
|
GO:0006464 protein modification |
|
GO:0008475 procollagen-lysine 5-dioxygenase activity |
|
GO:0008544 epidermis development |
|
GO:0016020 membrane |
|
GO:0016491 oxidoreductase activity |
|
GO:0016702 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen |
NCBI Gene |
Gene ID:5351 |
NCBI GTR |
153454 PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE; PLOD1 |
|
225400 EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 1; EDSKSCL1 |
OMIM |
153454 PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE; PLOD1 |
|
225400 EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 1; EDSKSCL1 |
Omim Description |
EDS VI |
|
EDS6 |
|
EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE |
|
EHLERS-DANLOS SYNDROME, TYPE VI |
|
|